Veterans SPORT Act

**1. What Happened & Status:** The Veterans SPORT Act (S.3138), introduced by Sen. Jim Banks (R-IN) on November 6, 2025, was ordered to be reported favorably out of the Senate Committee on Veterans' Affairs on March 18, 2026, with an amendment in the nature of a substitute. It awaits floor action in the Senate. A companion bill (H.R.1971) exists in the House, forwarded by subcommittee to full committee. The bill is active, bipartisan (cosponsors include Sen. King, I-ME), and has cleared its first legislative hurdle. **2. The Money Trail:** This is an AUTHORIZATION bill — it amends 38 U.S.C. §1701 to INCLUDE adaptive sports prosthetics within the definition of 'medical services' the VA must furnish. Unlike procurement-specific authorizations, this is effectively a MANDATE: once enacted, the VA has a legal obligation to provide these devices to eligible veterans who need them. This is NOT capped by the bill itself; the funding comes from VA's existing medical services appropriation (which exceeds $120B annually) and the mandatory spending nature means the VA must reallocate or request supplemental funding. No new separate appropriation is required, but actual procurement volume depends on VA budget execution. The VA currently serves approximately 110,000 veterans with major limb loss; even a 2-5% uptake for sports devices creates a $10M-$50M annual market. **3. Structural Winners & Losers:** WINNERS: Zimmer Biomet ($ZBH) is the largest US-based pure-play manufacturer of lower-extremity prosthetic components through its Orthopedics division. Its extremities product line includes sports-specific feet, knees, and terminal devices that exactly match the bill's scope. Baxter ($BAX) benefits indirectly via its Hill-Rom rehabilitation equipment portfolio sold into VA hospitals. $STAA (STAAR Surgical, eye lenses) and $STRR (Star Equity, construction) are NOT affected — STAA serves ophthalmology, not prosthetics; STRR is a construction/manufacturing conglomerate with no VA prosthetic exposure. Potential losers: no direct losers, but if VA reallocates from general orthopedic procurement to fund sports prosthetics, incumbent non-sports prosthetic vendors could see volume shifts. **4. Real Market Data Analysis:** $ZBH is trading at $82.80, near its 52-week low of $81.35 and well below its 52-week high of $108.29. The stock has cratered -11.01% in the past 7 days and -6.51% in 30 days — this is a broad selloff unrelated to the SPORT Act (likely company-specific or sector-wide headwinds). $BAX is at $17.94, down -2.02% in 7 days but up +12.34% in 30 days. The divergence suggests $BAX has been recovering while $ZBH has been punished. The SPORT Act is NOT priced into either stock given recent action was a committee step on March 18 — the market has largely ignored it. If the bill reaches the Senate floor, ZBH could see a catalyst-driven bounce. **5. Timeline:** Next steps: (1) Senate floor consideration — no date set, but senator-sponsor Banks is a Republican and the bill is non-controversial with clear veteran benefit; (2) House companion (H.R.1971) must pass or Senate bill must be passed and sent to House; (3) President signs. Given the 119th Congress runs through January 2027, the bill has a high probability of passing this year. Executive Order on mental health (April 18, 2026) is NOT directly related to prosthetics.